APA

Kosiborod M., Birkeland K. I., Cavender M. A., Fu A. Z., Wilding J. P., Khunti K., Holl R. W., Norhammar A., Jørgensen M. E., Wittbrodt E. T., Thuresson M., Bodegård J., Hammar N. & Fenici P. (20190114). Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. : Diabetes, obesity & metabolism.

Chicago

Kosiborod Mikhail, Birkeland Kåre I, Cavender Matthew A, Fu Alex Z, Wilding John P, Khunti Kamlesh, Holl Reinhard W, Norhammar Anna, Jørgensen Marit E, Wittbrodt Eric T, Thuresson Marcus, Bodegård Johan, Hammar Niklas and Fenici Peter. 20190114. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. : Diabetes, obesity & metabolism.

Harvard

Kosiborod M., Birkeland K. I., Cavender M. A., Fu A. Z., Wilding J. P., Khunti K., Holl R. W., Norhammar A., Jørgensen M. E., Wittbrodt E. T., Thuresson M., Bodegård J., Hammar N. and Fenici P. (20190114). Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. : Diabetes, obesity & metabolism.

MLA

Kosiborod Mikhail, Birkeland Kåre I, Cavender Matthew A, Fu Alex Z, Wilding John P, Khunti Kamlesh, Holl Reinhard W, Norhammar Anna, Jørgensen Marit E, Wittbrodt Eric T, Thuresson Marcus, Bodegård Johan, Hammar Niklas and Fenici Peter. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. : Diabetes, obesity & metabolism. 20190114.